Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. Active Biotech was established by Bo Håkansson and other associates in 1983 as an investment company named
Active i Malmö AB. The original objective of Active was to create value by acquiring and developing a diverse portfolio
of holdings in small- and medium-sized companies with a view to disposing of them upon suitable market opportunities.
Active entered the biotechnology sector in 1985 when it began to fund a research project in the field of bacterial
proteins, headed by Professor Lars Björck at Lund University.